Instil Bio Inc Stock News

Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. SYN-2510 targets the promising PD-L1/VEGF oncology pathway. The company recently licensed assets from ImmuneOnco Biopharmaceuticals, retaining commercialization rights outside Greater China and enhancing its global market positioning. SYN-2510 is advancing to Phase 2 trials for NSCLC and TNBC, addressing a TAM foreca...

Summit Therapeutics' stock is way up in response to clinical trial results that suggest the cancer therapy it's developing could become the standard of care for lots of patients. Instil Bio stock soared because it's developing a bispecific antibody similar to the candidate that pushed up Summit Therapeutics.

DALLAS and SHANGHAI, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541, “ImmuneOnco”) announced today the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in front-line non-small cell lung cancer (NSCLC) and in front-line triple-negative b...

Instil Bio is developing a bispecific antibody that strengthens immune responses to solid tumors by simultaneously targeting PD-L1 and VEGF. Instil Bio's lead immunology candidate is still in phase 1 testing, but a similar candidate from Summit Therapeutics recently outperformed Keytruda.

Instil Bio, Inc. in-licensing brings on board high demand IMM2510 clinical product with PD-L1/VEGF targeting of solid tumors; proof-of-concept established by Summit/Akeso and BioNTech. Two competitive advantages of IMM2510 would be the ability to bind to other VEGF ligands beyond that of VEGF-A only and to have enhanced ADCC killing. In-licensing deal with ImmuneOnco also brings on board next-g...

DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2024 financial results and provided a corporate update.

DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced a definitive agreement pursuant to which Instil is in-licensing ex-China development and commercial rights to ImmueOnco's proprietary PD-L1xVEGF bispecific antibody, IMM2510, as well as its next-gene...